Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Working Knowledge
Business Research for Business Leaders
  • Browse All Articles
  • Popular Articles
  • Cold Call Podcast
  • Managing the Future of Work Podcast
  • About Us
  • Book
  • Leadership
  • Marketing
  • Finance
  • Management
  • Entrepreneurship
  • All Topics...
  • Topics
    • COVID-19
    • Entrepreneurship
    • Finance
    • Gender
    • Globalization
    • Leadership
    • Management
    • Negotiation
    • Social Enterprise
    • Strategy
  • Sections
    • Book
    • Podcasts
    • HBS Case
    • In Practice
    • Lessons from the Classroom
    • Op-Ed
    • Research & Ideas
    • Research Event
    • Sharpening Your Skills
    • What Do You Think?
    • Working Paper Summaries
  • Browse All
    Private and Social Returns to R&D: Drug Development and Demographics
    22 Feb 2021Working Paper Summaries

    Private and Social Returns to R&D: Drug Development and Demographics

    by Efraim Benmelech, Janice Eberly, Dimitris Papanikolaou, and Joshua Krieger
    Research and development (R&D) by pharmaceutical firms focuses disproportionately on medical conditions afflicting the elderly. The proportion of R&D spending targeting older age groups is increasing over time. Even though these investments in R&D prolong life expectancy and improve quality of life, they have little effect on measured productivity and output growth.
    LinkedIn
    Email

    Author Abstract

    Investment in intangible capital—in particular, research and development—increased dramatically since the 1990s. However, output and measured productivity growth remains sluggish in recent years. One potential reason is that a significant share of the increase in intangible investment is geared toward consumer products such as pharmaceutical drugs that are not included in measured economic output. We document that a significant fraction of total R&D spending in the U.S. economy is done by pharmaceutical firms and is geared to developing drugs for the elderly. Increased life expectancy among the elderly increases welfare, but is not reflected in estimates of total factor productivity.

    Paper Information

    • Full Working Paper Text
    • Working Paper Publication Date: January 2021
    • HBS Working Paper Number: 21-083
    • Faculty Unit(s): Entrepreneurial Management
      Trending
        • 17 Jan 2023
        • In Practice

        8 Trends to Watch in 2023

        • 24 Jan 2023
        • Research & Ideas

        Passion at Work Is a Good Thing—But Only If Bosses Know How to Manage It

        • 10 Jan 2023
        • Research & Ideas

        How to Live Happier in 2023: Diversify Your Social Circle

        • 25 Jan 2022
        • Research & Ideas

        More Proof That Money Can Buy Happiness (or a Life with Less Stress)

        • 27 Jan 2023
        • Op-Ed

        Have We Lost Sight of Integrity?

    Joshua Lev Krieger
    Joshua Lev Krieger
    Assistant Professor of Business Administration
    Contact
    Send an email
    → More Articles
    Find Related Articles
    • Research and Development
    • Innovation and Invention
    • Health Care and Treatment
    • Pharmaceutical

    Sign up for our weekly newsletter

    Interested in improving your business? Learn about fresh research and ideas from Harvard Business School faculty.
    ǁ
    Campus Map
    Harvard Business School Working Knowledge
    Baker Library | Bloomberg Center
    Soldiers Field
    Boston, MA 02163
    Email: Editor-in-Chief
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College